1. Home
  2. CPOP vs BCDA Comparison

CPOP vs BCDA Comparison

Compare CPOP & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pop Culture Group Co. Ltd

CPOP

Pop Culture Group Co. Ltd

HOLD

Current Price

$0.36

Market Cap

11.9M

ML Signal

HOLD

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$0.78

Market Cap

13.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPOP
BCDA
Founded
2007
N/A
Country
China
United States
Employees
N/A
21
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.9M
13.6M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CPOP
BCDA
Price
$0.36
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
13.2M
359.4K
Earning Date
11-17-2025
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.75
52 Week High
$2.60
$2.29

Technical Indicators

Market Signals
Indicator
CPOP
BCDA
Relative Strength Index (RSI) 50.31 36.30
Support Level $0.05 N/A
Resistance Level $0.36 $1.29
Average True Range (ATR) 0.07 0.08
MACD 0.00 -0.01
Stochastic Oscillator 51.03 11.83

Price Performance

Historical Comparison
CPOP
BCDA

About CPOP Pop Culture Group Co. Ltd

Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: